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Abstract: Current treatment of unilateral breast cancer-related lymphedema 
(BCRL) is only directed to the afflicted arm. Near-infrared fluorescent 
imaging (NIRF) of arm lymphatic vessel architecture and function in BCRL 
and control subjects revealed a trend of increased lymphatic abnormalities 
in both the afflicted and unafflicted arms with increasing time after 
lymphedema onset. These pilot results show that BCRL may progress to 
affect the clinically “normal” arm, and suggest that cancer-related 
lymphedema may become a systemic, rather than local, malady. These 
findings support further study to understand the etiology of cancer-related 
lymphedema and lead to better diagnostics and therapeutics directed to the 
systemic lymphatic system. 
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1. Introduction 
Axillary lymph node dissection (ALND) has been a part of standard surgical treatment of 
breast cancer, enabling regional control of the disease and reliable staging based upon the 
identification of nodal metastases. ALND, however, is also associated with unacceptable 
surgical morbidities, particularly breast cancer-related lymphedema (BCRL), a disfiguring, 
debilitating disease that has no cure. Sentinel lymph node dissection (SLND) enables staging 
from the tumor-draining axillary lymph nodes with reduced risk of morbidity [1], but ALND 
remains the standard of practice if sentinel lymph nodes (SLNs) are found to contain 
metastases. While BCRL is less associated with cancer survivors who undergo SLND 
compared to those who undergo ALND, SLND alone still carries risk for BCRL. 
Reports of incidence rates of lymphedema vary widely, but a recent study found that, 
depending on criteria used, 43% to 94% of all breast cancer survivors developed lymphedema 
within 60 months post-operatively [2]. It is noteworthy that lymphedema is also prevalent 
after other cancer surgeries besides ALND and SLND: 20% of cervical cancer survivors [3] 
and many prostate cancer survivors [4,5] suffer lower-extremity lymphedema. Extended 
pelvic lymph node dissection (ePLND) in bladder, prostate, and melanoma surgeries is also 
associated with high incidence rates of lymphedema [6–11]. 
The etiology of lymphedema is not well understood. Lymph node removal and radiation 
treatment is thought to impair the normal lymphatic function of transporting excess fluid and 
macromolecules away from tissues for return to the blood vasculature. When the lymphatic 
vasculature is impaired, or becomes overwhelmed over time, fluid and macromolecule 
buildup occurs, leading to irresolvable and progressive swelling. If left untreated, 
lymphedema is disfiguring, and patients are prone to infections, fibrosis, depression, certain 
sarcomas, sepsis, and arthritis [12–14]. While some patients respond to treatment regimens of 
complete decongestive therapy (CDT), which includes manual lymphatic drainage (MLD), 
compression bandaging, therapeutic exercise, and meticulous skin care, only 59.1% of 
patients with arm lymphedema respond over a treatment period of 12 months [15]. 
To date, there has been no accepted method with sufficient spatial resolution to non-
invasively image the lymphatics and their function [16]. Recently, we developed a near-
infrared fluorescence (NIRF) imaging technique that demonstrated the feasibility of imaging 
lymphatics in normal controls and persons suffering lymphedema [17,18], as well as 
lymphatic functional response to MLD and pneumatic compression devices [19,20]. NIRF 
imaging depends upon the intradermal administration of the fluorescent dye indocyanine 
green (ICG), which is actively taken up by the initial lymphatics in the dermis and transits to 
collecting lymphatics through a series of lymphangions, or segments of “pumping” vessels, 
that conduct lymph to draining lymph node basins. Upon illuminating tissues with dim, 
tissue-penetrating NIR light, ICG-laden lymph generates fluorescence which is then collected 
to generate dynamic lymphatic imaging [21]. As part of a larger study, we recently imaged a 
number of BCRL subjects with a variety of lymphatic anomalies and observed a trend of 
prevalence in both affected and unaffected arms with time after the initial onset of 
lymphedema symptoms. This contribution describes collected images, associates time 
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affected and unaffected limbs, and suggests that cancer related-lymphedema may become a 
systemic, rather than local, malady. 
2. Methods 
2.1. Participants/subject population 
The protocol used for this study was approved by the U.S. Food and Drug Administration 
under a combinational investigational new drug application for the off-label  use of 
indocyanine green as a NIRF contrast agent (IND #102,827, NCT00833599, “Imaging 
lymphatic function in normal subjects and in persons with lymphatic disorders”). The studies 
were approved by the University of Texas Health Science Center institutional review board. 
Written informed consent was gathered from all participants—18 BCRL subjects and 6 
normal control subjects. The BCRL subjects (age 45–68, 17 women and 1 man) self-reported 
times since cancer treatment and the onset of BRCL. The NIRF imaging results from BCRL 
subjects were classified into 3 groups: (i) 6 months or less, (ii) between 1 and 2 years, and (iii) 
greater than 5 years since self-reported onset of BCRL symptoms. Normal subjects ranged 
from 26 to 68 years of age, and included 5 women and 1 man. 
2.2. Instruments for NIRF imaging 
The investigational imaging system depicted in Fig. 1 is described elsewhere [17–22]. Briefly, 
each system consists of a 785-nm excitation light source, a NIR-sensitive Gen III (model 
FS9910C) image intensifier, and a customized charge-coupled device (CCD) 16-bit camera 
outfitted with filters to selectively collect ICG fluorescence at 830 nm. The imaging field of 
view is determined by the distance of the camera from the subject and ranges from ~15  
 
Fig. 1. System used for NIRF lymphatic imaging. (a) Each system consists of a 785-nm 
excitation light source, a NIR-sensitive image intensifier, and a customized charge-coupled 
device (CCD) camera outfitted with filters to selectively collect ICG fluorescence at 830 nm. 
The emitted excitation light covered a maximal tissue surface area of approximately 900 cm
2. 
Injected ICG typically entered lymphatic capillaries near injection sites, and then moved into 
pre-collector and collector lymphatic vessels in subject arms. (b) Indocyanine green (ICG) is 
injected intradermally for uptake by dermal lymphatic capillaries, which feed into lymphatic 
pre-collector and collector vessels. 
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resolution  is approximately 1.26 line pairs per millimeter, as determined using the 1951 
United States Air Force resolution test chart. Excitation at 785 nanometers was used, because 
785 nm laser diodes are readily available, and this wavelength is near the peak excitation of 
the fluorophore used, indocyanine green (780 nm). The emitted excitation light illuminated a 
maximal tissue surface area of approximately 900 cm
2, resulting in an incident laser diode 
power of <1.9 mW/cm
2. An exposure time of 200 milliseconds per image permitted near real-
time imaging of the lymphatics. The field of view varies according to distance between 
camera and subject (6-3 inches), and depths of 3–4 centimeters are routinely imaged. 
2.3. Procedures 
Twelve injections each of 0.1 cc of 0.25 mg/ml indocyanine green were administered 
intradermally at the following anatomical locations: two injections dorsally on each hand, two 
in the medial and lateral ventral sides of each wrist, and two in the upper lateral area of each 
forearm, for a total dose of 300 micrograms. Injection sites were covered with small round 
adhesive bandages, and sometimes with black vinyl tape, to prevent camera saturation from 
intense fluorescence. Immediately following ICG administration, subjects were imaged. The 
following views were collected: (i) the dorsal hand, (ii) the dorsal forearm, (iii) the ventral 
forearm, (iv) the medial view of the elbow, and (v) the axilla. 
2.4. Analysis 
Images were loaded into ImageJ software (NIH) for analysis, and presented as still images or 
a movie compilation of still images. Images were evaluated for lymphovascular anomalies. 
For each NIRF image of the lymphatic vessels in hand, forearm, elbow and axilla views, the 
numbers of abnormalities in affected and unaffected arms of BCRL subjects were assessed by 
consensus of authors. 
3. Results 
3.1. Control subjects present with normal lymphatic architecture 
Figure 2  provides NIRF images of a single subject that is representative of all normal 
controls. As shown in Fig. 2(a), typical images of the hand consist of two major lymphatic 
vessel bundles draining from the injection sites and into the forearm. No distal flow of ICG 
toward fingers or toward the palms was observed in normal subjects. The dorsal view of the 
forearms (Fig. 2[b]) typically displayed the delivery of lymph to the upper arm through the 
lymphatic bundles that drained dorsal injection sites in the hand. Typical drainage patterns 
associated with medial and lateral wrist injections are seen in the ventral view of the forearm 
(Fig. 2[c]), along with numerous lymphatic vessels. ICG-laden lymph “packets,” presumably 
within lymphangions, are readily identified, and some brachial lymph nodes are visible. 
Images of the elbow (Fig. 2[d]) typically displayed numerous lymph vessels in the forearm  
 
Fig. 2. Near-infrared images of lymphatic vessels in (a) dorsal hand, (b) dorsal forearm, (c) 
ventral forearm, (d) medial elbow, and (e) axilla of a healthy control subject. Yellow scale bars 
= 5 cm. 
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Fig. 3. “Pumping,” or lymphatic propulsion, in a normal healthy control subject arm. Lymph 
“packets” are visible moving from valve to valve along lymphatic vessels (Media 1). Shown 
are multiple lymphatic vessels in a normal, healthy control ventral forearm. 
and upper arm areas, sometimes with “packets” of ICG-laden lymph collecting at sites of 
presumed lymphangions before being “pumped” through contractile motions to the next 
lymphangions (Fig. 3, Media 1). Axilla images were taken while the arm was positioned over 
the head, and displayed vessels actively pumping ICG-laden lymph to axillary lymph nodes 
(Fig. 2[e]). In summary, all control subjects exhibited active ICG transport within straight 
lymphatic vessels and confinement of extravascular ICG to within a 0.5 cm radius of the 
intradermal injection site. 
3.2. Aberrant lymphatic vessel architecture is evident in BCRL subjects 
NIRF imaging of lymphedema subjects revealed departures from normal lymphatic vessel 
architecture in both diagnosed as well as contralateral, unaffected arms. Examples of the 
lymphatic phenotypes typically seen in BCRL subjects are depicted in Fig. 4. While we and 
others have noted these distinct phenotypes in patients with lymphedema [17,18,23], we 
reintroduce them here in the context of our imaging of BCRL as a function of time after onset. 
Fine hyperplasia of vessels/tortuous lymphatic bundles (Fig. 4[a], top). In some subjects, 
small ICG-laden capillary lymphatic vessels were observed in the dermis, far from the site of 
injection. In some cases these dermal regions filled with ICG-laden lymph via conducting 
lymphatic vessels that could be seen actively pumping lymph. It remains unknown whether 
these apparently hyperplasic dermal regions are regions of new lymphatic vessel growth 
(termed lymphangiogenesis) or are normally present, dermal lymphatics that have 
“backfilled” with ICG-laden lymph. 
Tortuous lymphatic vessels (Fig. 4[a], bottom). Tortuous main conducting vessels, as well 
as capillary lymphatic vessels, were seen in lymphedema subjects, but only rarely in normal 
subjects. Lymph transport in these lymphatic vessels appeared to deviate from the normal 
distal-to-proximal direction [17,18]. These vessels were typically dilated, filled completely 
with ICG, and did not “pump” ICG-laden lymph between lymphangions as actively as normal 
lymphatic vascular bundles. 
Extravascular ICG (Figs. 4[b] and 4[c]). ICG was not associated with any apparent vessel, 
suggestive of lack of uptake by the initial lymphatic capillaries and extravascular transport. In 
some cases, ICG was even seen to diffuse distally from the site of injection towards the palm 
and fingers. Sometimes this extravascular ICG remained at or very near the site of ICG 
injection (nonmobile), and sometimes the ICG was found at a distance from the ICG injection 
site (mobile). 
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Fig. 4. Typical lymphatic architectural anomalies observed in BCRL subjects. (a) 
Hyperplasia/tortuous lymphatic vessels located on the medial elbow of a BCRL subject 13 
years after onset (top) and the dorsal forearm of a subject 5 years after BCRL onset (bottom), 
(b) nonmobile extravascular ICG/hypoplasia on a dorsal hand of a subject 6 months after 
BCRL onset (top) and a dorsal forearm of a subject 6 months after BCRL onset (bottom), (c) 
mobile extravascular ICG/hypoplasia on the lateral forearm of a subject 6 months after BCRL 
onset (top) and on a medial elbow of a subject 6 months after BCRL onset (bottom), (d) 
punctuated ICG “clusters” located on the lateral forearm of a subject 5 years after BCRL onset 
(top) and on a lateral forearm of a subject 5 years after BCRL onset (bottom). Yellow scale 
bars = 5 cm. 
Punctuated extravascular  deposits of ICG (Fig. 4[d]). These previously reported 
architectural features [17–20] consist of “clusters” of extravascular ICG within the dermis. 
These clusters may arise due to backflow of ICG-laden lymph into the small initial lymphatics 
that normally  drain the dermis. The association of ICG with lymph proteins may be 
responsible for the fluorescent “clusters” within the extravascular space. Adams et al. [19] 
reported the appearance of “starry-night” patterns after pneumatic compression treatment of 
an advanced BRCL subject, suggesting movement from the injection site to the dermis in a 
“backflow” condition not seen in normal subjects. The lymphatic vessel abnormalities 
visualized may develop in response to surgical, chemotherapeutical, or radiological damage, 
and may represent attempts to generate new lymphatic vessels, recruitment of normally 
underutilized vessels, or complete failure to use any vessels. 
Figure 5 displays images from a group 3 representative, in which imaging was performed 
five years after lymphedema onset. Aberrations in the affected and contralateral, “unaffected” 
arm are notable, and include several types of anomalies, illustrating the heterogeneity of 
lymphatic abnormalities present. 
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Fig. 5. Unaffected and affected (b) arms from one subject in group 3 (5 years since BCRL 
onset). Blue arrows = tortuous vessels/hyperplasia, yellow arrows = nonmobile extravascular 
ICG, white arrows = mobile extravascular ICG. Yellow scale bars = 5 cm. 
3.3. Presence of lymphatic vessel architectural aberrations increases with time after onset of 
BCRL 
Phenotypical abnormalities of lymphatics were assessed for each subject, and the 
abnormalities were tallied according to time since lymphedema onset. This retrospective 
analysis was designed to discover lymphatic phenotypes and was not powered to find 
differences between affected and unaffected arms of BCRL subjects as a function of time 
from initial onset of symptoms. Nonetheless, Fig. 6 shows the percentage of BCRL subjects 
in each group with onset of symptoms at (i) ≤6 months, (ii) between 6 months and 2 years, 
and (iii) greater than 5 years, exhibiting lymphatic abnormalities in affected and unaffected 
arms in the hands, ventral and dorsal forearms, elbows, and axilla. 
 
Fig. 6. Percent of images with architectural aberrations. Percent of (a) hands, (b) dorsal 
forearms, (c) ventral forearms, (d) medial elbows, and (e) axillary regions displaying lymphatic 
anomalies in groups 1 (6 months or less since onset), 2 (1-2 years since onset), and 3 (more 
than 5 years since onset). 
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toward increased lymphatic alterations with increased time from onset of symptoms is 
evident. Notably, both affected and “unaffected” arms display aberrations with increased time 
after BCRL onset. 
4. Discussion 
BCRL is currently diagnosed when arm volume increases beyond 20% of baseline 
measurements, or 20% of current contralateral, unaffected arm volume. Recent studies of 
breast cancer survivors  at risk for BCRL found that earlier initiation of lymphedema 
management resulted in better outcome, and even complete resolution of BCRL [24,25]. Our 
study provided single “snapshots” of increased aberrant lymphatic architecture with time after 
self-reported onset of BCRL symptoms, and, remarkably, increased lymphatic anomalies in 
both afflicted and unafflicted arms were observed. If substantiated with longitudinal studies of 
individual subjects, these results have several clinical implications: 
1. Current  diagnosis of BCRL based upon differential afflicted and unafflicted arm 
volumes could result in underdiagnosis or late diagnosis, and could negatively 
impact the efficiencies of current manual therapies [24,25]. 
2. If systemic lymphatic dysfunction is a characteristic of BCRL, as this study suggests, 
then effective management should also include the contralateral arm and truncal 
lymphatic basins. 
The technique of NIRF imaging used in this study is especially amenable to longitudinal 
studies, as it (i) requires no cannulation of lymphatic vessels, (ii) involves low dose (25 ug) 
and low volume (0.1 cc) administration of a dye that has a longstanding history of patient 
safety and rapid clearance (<2 minutes) through the hepatocirculatory system once it reaches 
the blood vasculature, and (iii) unlike emerging MRI (magnetic resonance) and CT (computed 
tomography) with lymphangiography agents [26,27], NIRF imaging distinguished the mixture 
of both functional and dysfunctional vessels observed in the early stages of BCRL, not just 
clearance rates of imaging agent. Because imaging is rapid (~200 milliseconds), involves a 
nonradioactive contrast agent, and provides both higher temporal and spatial resolution than 
conventional lymphoscintigraphy [21], repeated imaging can be routinely performed to 
evaluate change in lymphatic function with therapy. 
The exact etiology of breast cancer-related lymphedema (BCRL) remains a mystery. The 
number of lymph nodes surgically removed has been reported to not affect cancer survival 
[28,29], although more extensive ALND and the addition of axillary radiation therapy 
increase risk of lymphedema [30,31]. A genetic predisposition for lymphatic dysfunction, 
other surgical or injury damage to lymphatics, body mass index, medications, and fitness level 
are all suspected systemic factors contributing to the development of lymphedema [32,33]. 
Using NIRF to capture a single snapshot of disease progression in a number of BCRL 
patients, we show the tendency not only for increased lymphatic abnormality, but potentially 
systemic involvement. Recently, in a study of unilateral lower extremity lymphedema 
patients, Burnand et al. used lymphoscintigraphy to monitor the percentage of 99mcTc that 
accumulated in the ilioinguinal regions 60 to 180 minutes after subcutaneous injection in the 
webspaces of the feet to show that clinically “normal” contralateral legs of patients with 
unilateral leg lymphedema also possessed lymphatic dysfunction [34]. Although their patient 
population was comprised of primary (hereditary and congenital) lymphedema subjects and 
their results showing bilateral disease might be expected, their results are nonetheless 
consistent with the trends observed in this study of BCRL. In two other studies of BCRL 
patients, rates of depot clearance after subcutaneous injection of radiolabeled protein in the 
hands and subsequent appearance in venous blood suggested lymphatic dysfunction in both 
affected and contralateral “normal” arms [35,36]. 
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subject to inaccuracy. Although H&Ps (health and physical reports written by an examining 
physician or other health care professional at time of consult) were used to compile 
background information, much of the information in these documents is subject-reported. 
Although subjects were asked to drink fluids before imaging sessions, hydration level 
variations were inevitable, possibly affecting results. Perhaps most importantly, study subjects 
received varying levels of lymphedema care and started therapy at different time points after 
onset, and these differences could affect outcomes [24,25]. Longitudinal imaging studies are 
needed to evaluate lymphatic remodeling that may occur prior to onset of BCRL symptoms, 
and further progress to include other body parts beyond the affected arm. Correlation of 
percent arm volume change with extent of lymphatic vessel architectural abnormalities could 
be documented in such prospective studies, similarly to published quantitative studies [37]. 
NIRF allow visualization of lymphatic vessels up to 4 centimeters deep. While other imaging 
modalities like photo-acoustic tomography (PAT) can image vascular structures at greater 
depths, PAT has no absorber in lymph for imaging. Finally, because NIRF is an 
investigational imaging technique, we were unable to combine with other confirmatory 
conventional imaging modalities, such as lymphoscintigraphy or rates of depot clearance of 
radiolabeled protein. 
Lymphatic architectural abnormalities which varied widely in location were found in both 
the affected as well as unaffected, contralateral arms of subjects with BCRL, suggesting the 
disease may manifest itself systemically rather than locally. Since our retrospective evaluation 
demonstrated a trend of increased prevalence of lymphatic architectural abnormalities with 
increasing time since onset of symptoms, further studies need to determine whether systemic 
manifestation of lymphatic abnormalities in cancer-related lymphedema are indicative of 
progressive disease, or whether these abnormalities were present previously, but manifested in 
lymphatic overload only after cancer treatment. 
5. Conclusions 
This study illustrates the usefulness of NIRF imaging to track lymphatic aberration 
development in BCRL.  The technology could also direct therapy, diagnosis, and even 
evaluate new radioprotective treatments [38]. The appearance of vessel abnormalities on 
unaffected arms with increasing time suggests that lymphedema has a systemic causal 
component, and that care should be given to both arms after cancer treatment. This study 
describes the apparent progression of BCRL by imaging lymphatic vasculature, and may 
provide key clues to causes, as well as providing impetus to encourage early, aggressive 
detection and treatment. 
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